2022
Oral Cyanobacteria and hepatocellular carcinoma
Hernandez BY, Zhu X, Risch HA, Lu L, Ma X, Irwin ML, Lim JK, Taddei TH, Pawlish KS, Stroup AM, Brown R, Wang Z, Wong LL, Yu H. Oral Cyanobacteria and hepatocellular carcinoma. Cancer Epidemiology Biomarkers & Prevention 2022, 31: cebp.epi-21-0804-a.2021. PMID: 34697061, PMCID: PMC8755591, DOI: 10.1158/1055-9965.epi-21-0804.Peer-Reviewed Original ResearchConceptsHepatitis B virusHepatitis C virusHepatocellular carcinomaRisk factorsLiver diseaseHCC casesOral microbiomeU.S. case-control studyIndependent risk factorChronic liver diseaseFatty liver diseaseHCC risk factorsGut microbial alterationsType 2 diabetesCase-control studyLiver cancer developmentNSAID useAspirin useC virusB virusHCC riskNegative historyOral samplesSignificant associationCancer development
2021
Tiliroside as a CAXII inhibitor suppresses liver cancer development and modulates E2Fs/Caspase-3 axis
Han R, Yang H, Lu L, Lin L. Tiliroside as a CAXII inhibitor suppresses liver cancer development and modulates E2Fs/Caspase-3 axis. Scientific Reports 2021, 11: 8626. PMID: 33883691, PMCID: PMC8060393, DOI: 10.1038/s41598-021-88133-7.Peer-Reviewed Original ResearchConceptsLiver cancer developmentLiver cancerCancer developmentLiver cancer cell linesCD133 expression levelsAnti-proliferation effectQuantitative reverse transcription PCRCancer cell linesCancer deathTHLE-3THLE-3 cellsAlternative therapiesReverse transcription-PCREffective therapyFatal causeNC groupTherapeutic implicationsInvasion assaysTherapeutic useClinic practiceELISA kitHigher anti-proliferation effectColony formationTranscription-PCRAnticancer efficacy